GRG Therapeutics
Who we are
GRG Therapeutics, founded by Dr. Fei Geng at McMaster University in 2022, is a clinical-stage therapeutic company dedicated to revolutionizing the treatment of autoimmune diseases. Our primary focus is on developing innovative in vivo CAR T cell therapies using cutting-edge genome editing techniques. By leveraging these advanced technologies, we aim to achieve enhanced clonal expansion of CAR T cells within the disease microenvironment, providing more effective and precise treatments for patients. At GRG Therapeutics, we are committed to advancing the field of immunotherapy and improving patient outcomes through rigorous research, clinical trials, and collaboration with leading experts in the industry. Our mission is to transform the landscape of autoimmune disease therapy and bring hope to patients worldwide.
Mission
At GRG Therapeutics, our mission is to revolutionize the treatment of autoimmune diseases through the development of innovative in vivo CAR T cell therapies. We are committed to leveraging cutting-edge genome editing technologies to achieve enhanced clonal expansion of CAR T cells, providing more precise and effective treatments for patients. Through rigorous research, clinical trials, and collaboration with leading experts, we aim to transform the landscape of autoimmune disease therapy and improve patient outcomes.
​
​
Vision
Our vision is to be a global leader in the field of immunotherapy, pioneering the development of in vivo CAR T cell therapies that offer new hope and improved quality of life for patients with autoimmune diseases. We aspire to advance scientific knowledge, foster innovation, and drive the future of personalized medicine. By transforming how autoimmune diseases are treated, we aim to create a world where these conditions can be effectively managed or cured, ensuring a healthier and brighter future for all.
